指南与共识乳腺癌放疗

乳腺癌临床试验中放射治疗报告的基本要求:欧洲放射治疗与肿瘤学会(ESTRO)认可的国际多学科共识

Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO).
指南 / 共识 · Radiother Oncol · 2023-12-19

欧洲放射治疗与肿瘤学会(ESTRO)认可的国际乳腺癌专家共识通过改良德尔菲流程制定,于2023年6月在意大利佛罗伦萨的国际会议上展示。该共识提出放射治疗报告的最佳要求和基本要求,并设计了可供所有涉及放射治疗的乳腺癌临床试验使用的病例报告表模板。

要点

  • 最佳要求包括遵守预定义的放射治疗计划方案和集中化放射治疗质量保证。
  • 基本要求旨在减少放射治疗中与指南的差异和偏离,即使放射治疗不是试验的主要焦点。
  • 共识推荐在临床试验和日常临床常规中实施这些实践以生成高质量数据。

核心结论

  • 共识推荐在临床试验和日常临床常规中实施这些实践以生成高质量数据。
  • 最佳要求包括遵守预定义的放射治疗计划方案和集中化放射治疗质量保证。
  • 基本要求旨在减少放射治疗中与指南的差异和偏离,即使放射治疗不是试验的主要焦点。

研究设计与样本

  • 由国际乳腺癌专家通过改良德尔菲流程制定共识,并于2023年6月在意大利佛罗伦萨的国际会议上展示。
  • 该共识由欧洲放射治疗与肿瘤学会(ESTRO)认可。

主要发现

  • 共识推荐被视为最佳和基本标准,后者旨在定义最低要求。
  • 已设计病例报告表模板,可供所有涉及放射治疗的乳腺癌临床试验使用。

关键数值与推荐

  • 最佳要求包括遵守预定义的放射治疗计划方案和集中化放射治疗质量保证。
  • 基本要求旨在减少放射治疗中与指南的差异和偏离,即使放射治疗不是试验的主要焦点。

临床怎么用

  • 共识推荐在临床试验和日常临床常规中实施这些实践以生成高质量数据。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The European Society for Radiotherapy and Oncology (ESTRO) has advocated the establishment of guidelines to optimise precision radiotherapy (RT) in conjunction with contemporary therapeutics for cancer care. Quality assurance in RT (QART) plays a pivotal role in influencing treatment outcomes. Clinical trials incorporating QART protocols have demonstrated improved survival rates with minimal associated toxicity. Nonetheless, in routine clinical practice, there can be variability in the indications for RT, dosage, fractionation, and treatment planning, leading to uncertainty. In pivotal trials reporting outcomes of systemic therapy for breast cancer, there is limited information available regarding RT, and the potential interaction between modern systemic therapy and RT remains largely uncharted. This article is grounded in a consensus recommendation endorsed by ESTRO, formulated by international breast cancer experts. The consensus was reached through a modified Delphi process and was presented at an international meeting convened in Florence, Italy, in June 2023. These recommendations are regarded as both optimal and essential standards, with the latter aiming to define the minimum requirements. A template for a case report form (CRF) has been devised, which can be utilised by all clinical breast cancer trials involving RT. Optimal requirements include adherence to predefined RT planning protocols and centralised QART. Essential requirements aim to reduce variations and deviations from the guidelines in RT, even when RT is not the primary focus of the trial. These recommendations underscore the significance of implementing these practices in both clinical trials and daily clinical routines to generate high-quality data.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kaidar-Person O, Meattini I, Boersma LJ, et al. Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO). Radiother Oncol. 2023. PMID: 38122852. doi:10.1016/j.radonc.2023.110060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。